Laboratorio de Patologia Celular, Instituto de Anatomia, Histologia y Patologia, Universidad Austral de Chile, Valdivia Box 567, Chile.
World J Gastroenterol. 2012 Mar 21;18(11):1208-15. doi: 10.3748/wjg.v18.i11.1208.
To determine the expression of HER2 and bradykinin B(1) receptors (B(1)R) in the two pathogenic models of gallbladder cancer: the metaplasia-dysplasia-carcinoma and the adenoma-carcinoma pathways.
Receptor proteins were visualized by immunohistochemistry on 5-μm sections of paraffin-embedded tissue. Expression of both receptors was studied in biopsy samples from 92 patients (6 males and 86 females; age ranging from 28 to 86 years, mean 56 years). High HER2 expression in specimens was additionally investigated by fluorescence in situ hybridization. Cell proliferation in each sample was assessed by using the Ki-67 proliferation marker.
HER2 receptor protein was absent in adenomas and in normal gallbladder epithelium. On the contrary, there was intense staining for HER2 on the basolateral membrane of epithelial cells of intestinal metaplasia (22/24; 91.7%) and carcinoma in situ (9/10; 90%), the lesions that displayed a significantly high proliferation index. Protein up-regulation of HER2 in the epithelium with metaplasia or carcinoma in situ was not accompanied by HER2 gene amplification. A similar result was observed in invasive carcinomas (0/12). The B(1)R distribution pattern mirrored that of HER2 except that B(1)R was additionally observed in the adenomas. The B(1)R appeared either as cytoplasmic dots or labeling on the apical cell membrane of the cells composing the epithelia with intestinal metaplasia (24/24; 100%) and carcinoma in situ (10/10; 100%) and in the epithelial cells of adenomas. In contrast, both HER2 (4/12; 33%) and B(1)R (1/12; 8.3%) showed a low expression in invasive gallbladder carcinomas.
The up-regulation of HER2 and B(1)R in precursor lesions of gallbladder carcinoma suggests cross-talk between these two receptors that may be of importance in the modulation of cell proliferation in gallbladder carcinogenesis.
确定 HER2 和缓激肽 B(1) 受体 (B(1)R) 在两种胆囊癌发病模型中的表达:化生-异型增生-癌途径和腺瘤-癌途径。
通过免疫组织化学方法在石蜡包埋组织的 5μm 切片上显示受体蛋白。在 92 名患者(6 名男性和 86 名女性;年龄 28 至 86 岁,平均 56 岁)的活检样本中研究了两种受体的表达。通过荧光原位杂交进一步研究了标本中高 HER2 的表达。使用 Ki-67 增殖标志物评估每个样本中的细胞增殖。
HER2 受体蛋白在腺瘤和正常胆囊上皮中均不存在。相反,肠上皮化生(22/24;91.7%)和原位癌(9/10;90%)上皮细胞的基底外侧膜上有强烈的 HER2 染色,这些病变显示出明显高的增殖指数。具有化生或原位癌的上皮中 HER2 的蛋白上调不伴有 HER2 基因扩增。在侵袭性癌中也观察到类似的结果(0/12)。B(1)R 的分布模式与 HER2 相似,只是 B(1)R 还存在于腺瘤中。B(1)R 以细胞质点或肠上皮化生(24/24;100%)和原位癌(10/10;100%)上皮细胞的顶膜上的标记出现,也存在于腺瘤的上皮细胞中。相比之下,HER2(4/12;33%)和 B(1)R(1/12;8.3%)在侵袭性胆囊癌中的表达均较低。
胆囊癌前病变中 HER2 和 B(1)R 的上调表明这两种受体之间存在串扰,这可能对胆囊癌发生过程中细胞增殖的调节很重要。